Harmonia MentisHarmonia Mentis

  • Seizure Freedom is the Ultimate Goal of Seizure Management*

    *Seizure freedom was a secondary endpoint of the pivotal phase II trial C017; the primary endpoint was seizure reduction.1
    This webpage is intended for UK-I health care professionals.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events and product complaint should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard for the UK or www.hpra.ie for Ireland. Adverse events and product complaint should also be reported to Angelini Pharma on (UK) +44 2034889643, (IRE) +353 1 584 4671 or UKIReporting@angelinipharma.com

Discover ONTOZRY®▼ (cenobamate)

Clinical Practicalities

Seizure Freedom is the ultimate goal of seizure management

ONTOZRY® (cenobamate) On-Demand

Safety profile with ONTOZRY® (cenobamate)

Efficacy with ONTOZRY® (cenobamate)

Events and Resources

Reference: 1. Krauss GL, et al. Lancet Neurol. 2020;19(1):38-48.
UK23592P | June 2024

;